MedPath

The impact of whole body heating on blood flow distribution and temperature regulation in chronic heart failure patients

Not Applicable
Withdrawn
Conditions
ew York Heart Association Class I-III chronic heart failure (aetiology either ischaemic or idiopathic dilated cardiomyopathy)
New York Heart Association Class I-III chronic heart failure (aetiology either ischaemic or idiopathic dilated cardiomyopathy)
Cardiovascular - Other cardiovascular diseases
Registration Number
ACTRN12613000361707
Lead Sponsor
Royal Perth Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Withdrawn
Sex
All
Target Recruitment
100
Inclusion Criteria

Patients with New York Heart Association Class I-III CHF (aetiology either ischaemic or idiopathic dilated cardiomyopathy)

A group of subjects who do not have CHF will be recruited as controls. These control subjects will be matched for age, sex and body composition.

Exclusion Criteria

Recent history of syncope (past 6 months)
Systolic blood pressure < 90mmHg
New York Heart Association Class IV
Recent exacerbation of heart failure resulting in hospitalisation (< 2months)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Brachial, carotid and cerebral artery blood flow asssesed by high resolution ultrasonography[At baseline prior to randomisation and following the 10 week intervention. Additionally measurements will be taken at fortnightly intervals during the intervention.];Skin blood flow assessed by microdialysis infusion of locally acting blocking agents and laser Doppler flowmetry.[At baseline prior to randomisation and following the 10 week intervention. Additionally measurements will be taken at fortnightly intervals during the intervention.];Sweat rate production assessed by a water vapour vapour pressure sensitive capacitor.[At baseline prior to randomisation and following the 10 week intervention. Additionally measurements will be taken at fortnightly intervals during the intervention.]
Secondary Outcome Measures
NameTimeMethod
Skin and core body temperature assessed using external (skin) and internal (rectal) thermistors.[At baseline prior to randomisation and following the 10 week intervention. Additionally measurements will be taken at fortnightly intervals during the intervention.]
© Copyright 2025. All Rights Reserved by MedPath